

Protocol for Hyftor® (sirolimus) topical gel

Approved April 2023

Background: Facial angiofibroma is the most predominant cutaneous manifestation of tuberous sclerosis complex (TSC), a rare autosomal dominant genetic disorder impacting the mechanistic target of rapamycin (mTOR). Facial angiofibroma can bleed spontaneously, impair eyesight, and cause aesthetic disfiguration causing psychological and social stress.

Hyftor is an mTOR inhibitor immunosuppressant indicated for the treatment of facial angiofibroma associated with tuberous sclerosis in adults and pediatric patients 6 years of age and older.

Criteria for approval:

1. Patient has a diagnosis of facial angiofibroma associated with tuberous sclerosis;
AND
2. Patient is 6 years of age or older; **AND**
3. Patient has 3 or more papules of facial angiofibroma that are at least 2 mm in diameter with redness in each
4. Medication is prescribed by or in consultation with a dermatologist or a physician who specializes in the treatment of patients with tuberous sclerosis complex
5. Medication is prescribed in accordance with Food and Drug Administration (FDA) established indication and dosing regimens or in accordance with medically appropriate off-label indication and dosing according to American Hospital Formulary Service, Micromedex, Clinical Pharmacology, Wolters Kluwer Lexi-Drugs (Lexicomp), national guidelines, or other peer-reviewed evidence

Initial Approval: 3 months

Continuation of therapy:

1. There is significant improvement or stabilization in clinical signs and symptoms of disease (including but not limited to reduction in size or color of angiofibromas).
2. Medication is prescribed in accordance with Food and Drug Administration (FDA) established indication and dosing regimens or in accordance with medically appropriate off-label indication and dosing according to American Hospital Formulary Service, Micromedex, Clinical Pharmacology, Wolters Kluwer Lexi-Drugs (Lexicomp), national guidelines, or other peer-reviewed evidence

Renewal Approval: 6 months

References:

1. Hyftor [prescribing information]. Nobelpharma America, LLC, Bethesda, MD 20814. March 2022
2. Clinical Pharmacology® Gold Standard Series [Internet database]. Tampa FL. Elsevier 2019. Updated periodically
3. Lin, Y. et al. Efficacy and Safety of Topical Mechanistic Target of Rapamycin Inhibitors for Facial Angiofibromas in Patients with Tuberous Sclerosis Complex: A Systematic Review and Network Meta-Analysis. *Biomedicines* 2022, 10, 826. <https://doi.org/10.3390/biomedicines10040826>
4. Boggarapu, S., Roberds, S.L., Nakagawa, J. et al. Characterization and management of facial angiofibroma related to tuberous sclerosis complex in the United States: retrospective analysis of the natural history database. *Orphanet J Rare Dis* 17, 355 (2022). <https://doi.org/10.1186/s13023-022-02496-2>